Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Q Biomed Inc (QBIO)

Q Biomed Inc (QBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Q BioMed Inc. Provides Update to Shareholders PR Newswire - Fri Jun 23, 2023

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical...

QBIO : 0.0002 (+100.00%)
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe PR Newswire - Fri Apr 14, 2023

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical...

QBIO : 0.0002 (+100.00%)
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office PR Newswire - Fri Feb 10, 2023

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical...

QBIO : 0.0002 (+100.00%)
Q BIOMED PROVIDES SHAREHOLDER UPDATE PR Newswire - Tue Oct 11, 2022

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to provide an update to its...

QBIO : 0.0002 (+100.00%)
Q BioMed Inc. Provides Update to Shareholders PR Newswire - Fri Jul 29, 2022

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical...

QBIO : 0.0002 (+100.00%)
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer PR Newswire - Tue Jul 26, 2022

/PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the potential superior...

QBIO : 0.0002 (+100.00%)
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants FinancialNewsMedia - Wed Sep 22, 2021

Palm Beach, FL – September 22, 2021 – FinancialNewsMedia.com News Commentary – The U.S. government, via the American Rescue Plan, is investing more than $3 billion to accelerate the discovery,...

QBIO : 0.0002 (+100.00%)
CRVS : 1.4100 (+3.68%)
MRNA : 102.00 (-1.39%)
SRNE : 0.0240 (-14.29%)
CYDY : 0.1509 (+3.36%)
Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials – MAN-19 therapeutic program heading to clinical trial in early 2022 FinancialNewsMedia - Wed Sep 22, 2021

New York, NY –  September 22, 2021 – Q BioMed Inc. (OTCQB: QBIO ) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatment...

QBIO : 0.0002 (+100.00%)
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026 FinancialNewsMedia - Tue Aug 24, 2021

Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense...

QBIO : 0.0002 (+100.00%)
ABVC : 1.0500 (+2.94%)
TRIL : 18.44 (+2.62%)
CASI : 2.24 (unch)
SESN : 12.5760 (+7.29%)
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing FinancialNewsMedia - Tue Aug 24, 2021

New York, NY – August 24, 2021 – Q BioMed Inc. (OTCQB: QBIO ) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare...

QBIO : 0.0002 (+100.00%)

Barchart Exclusives

3 Energy Dividend Stocks Leading the S&P 500 Higher Barchart - Thu Apr 18, 6:30PM CDT
These three energy dividend stocks have outperformed the S&P 500 on a year-to-date basis, and rank among the index's top 20 performers of 2024 so far. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot